Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic Leukemia

Overview

Journal Pharmgenomics Pers Med

Publisher Dove Medical Press

Date 2020 Aug 28

PMID 32848445

Citations 6

Authors

Dimitri Maamari

Habib El-Khoury

Omran Saifi

Samar A Muwakkit

Nathalie K Zgheib

Affiliations

Soon will be listed here.

Abstract

Despite major advances in the management and high cure rates of childhood acute lymphoblastic leukemia (ALL), patients still suffer from many drug-induced toxicities, sometimes necessitating dose reduction, or halting of cytotoxic drugs with a secondary risk of disease relapse. In addition, investigators have noted significant inter-individual variability in drug toxicities and disease outcomes, hence the role of pharmacogenetics (PGx) in elucidating genetic polymorphisms in candidate genes for the optimization of disease management. In this review, we present the PGx data in association with main toxicities seen in children treated for ALL in addition to efficacy, with a focus on the most plausible germline PGx variants. We then follow with a summary of the highest evidence drug-gene annotations with suggestions to move forward in implementing preemptive PGx for the individualization of treatment regimens for children with ALL.

Citing Articles

Association between genetic variants of membrane transporters and the risk of high-grade hematologic adverse events in a cohort of Mexican children with B-cell acute lymphoblastic leukemia.

Escalante-Bautista D, Cerecedo D, Jimenez-Hernandez E, Gonzalez-Torres C, Gaytan-Cervantes J, Nunez-Enriquez J Front Oncol. 2024; 13:1276352.

PMID: 38269022 PMC: 10807790. DOI: 10.3389/fonc.2023.1276352.

Pharmacogenetics of pediatric acute lymphoblastic leukemia in Uruguay: adverse events related to induction phase drugs.

Burgueno-Rodriguez G, Mendez Y, Olano N, Schelotto M, Castillo L, Soler A Front Pharmacol. 2023; 14:1278769.

PMID: 38044950 PMC: 10690766. DOI: 10.3389/fphar.2023.1278769.

Translating Precision Health for Pediatrics: A Scoping Review.

Subasri M, Cressman C, Arje D, Schreyer L, Cooper E, Patel K Children (Basel). 2023; 10(5).

PMID: 37238445 PMC: 10217253. DOI: 10.3390/children10050897.

The Relevance of Telomerase and Telomere-Associated Proteins in B-Acute Lymphoblastic Leukemia.

da Mota T, Camargo R, Biojone E, Guimaraes A, Pittella-Silva F, de Oliveira D Genes (Basel). 2023; 14(3).

PMID: 36980962 PMC: 10048576. DOI: 10.3390/genes14030691.

Neurotoxicity Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy.

Sliwa-Tytko P, Kaczmarska A, Lejman M, Zawitkowska J Int J Mol Sci. 2022; 23(10).

PMID: 35628334 PMC: 9146746. DOI: 10.3390/ijms23105515.

References

Soler A, Olano N, Mendez Y, Lopes A, Silveira A, Dabezies A . TPMT and NUDT15 genes are both related to mercaptopurine intolerance in acute lymphoblastic leukaemia patients from Uruguay. Br J Haematol. 2017; 181(2):252-255. DOI: 10.1111/bjh.14532. View

Zgheib N, Akika R, Mahfouz R, Aridi C, Ghanem K, Saab R . NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon. Pediatr Blood Cancer. 2016; 64(1):146-150. DOI: 10.1002/pbc.26189. View

Fernandez C, Stewart E, Panetta J, Wilkinson M, Morrison A, Finkelman F . Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase. Cancer Chemother Pharmacol. 2014; 73(6):1307-13. PMC: 4137479. DOI: 10.1007/s00280-014-2464-2. View

Chen S, Pei D, Yang W, Cheng C, Jeha S, Cox N . Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther. 2010; 88(2):191-6. PMC: 3000799. DOI: 10.1038/clpt.2010.94. View

Moriyama T, Yang Y, Nishii R, Ariffin H, Liu C, Lin T . Novel variants in and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. Blood. 2017; 130(10):1209-1212. PMC: 5606007. DOI: 10.1182/blood-2017-05-782383. View

Zhang J, Fei T, Li Z, Zhu G, Wang L, Chen Y . BMP induces cochlin expression to facilitate self-renewal and suppress neural differentiation of mouse embryonic stem cells. J Biol Chem. 2013; 288(12):8053-8060. PMC: 3605624. DOI: 10.1074/jbc.M112.433995. View

Krynetski E, Schuetz J, Galpin A, Pui C, Relling M, Evans W . A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A. 1995; 92(4):949-53. PMC: 42614. DOI: 10.1073/pnas.92.4.949. View

Oosterom N, Berrevoets M, den Hoed M, Zolk O, Hoerning S, Pluijm S . The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2018; 28(10):223-229. DOI: 10.1097/FPC.0000000000000352. View

Gutierrez-Camino A, Martin-Guerrero I, Lopez-Lopez E, Echebarria-Barona A, Zabalza I, Ruiz I . Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. Pharmacogenet Genomics. 2015; 26(2):100-2. DOI: 10.1097/FPC.0000000000000191. View

10.

Gutierrez-Camino A, Oosterom N, den Hoed M, Lopez-Lopez E, Martin-Guerrero I, Pluijm S . The miR-1206 microRNA variant is associated with methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics. 2017; 27(8):303-306. DOI: 10.1097/FPC.0000000000000291. View

11.

Ongaro A, De Mattei M, Della Porta M, Rigolin G, Ambrosio C, Di Raimondo F . Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica. 2009; 94(10):1391-8. PMC: 2754955. DOI: 10.3324/haematol.2009.008326. View

12.

Weinshilboum R, Sladek S . Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980; 32(5):651-62. PMC: 1686086. View

13.

Tumer T, Ulusoy G, Adali O, Sahin G, Gozdasoglu S, Arinc E . The low frequency of defective TPMT alleles in Turkish population: a study on pediatric patients with acute lymphoblastic leukemia. Am J Hematol. 2007; 82(10):906-10. DOI: 10.1002/ajh.20947. View

14.

Smid A, Karas-Kuzelicki N, Jazbec J, Mlinaric-Rascan I . PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy. Sci Rep. 2016; 6:30244. PMC: 4958958. DOI: 10.1038/srep30244. View

15.

van der Wouden C, Cambon-Thomsen A, Cecchin E, Cheung K, Davila-Fajardo C, Deneer V . Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. Clin Pharmacol Ther. 2016; 101(3):341-358. DOI: 10.1002/cpt.602. View

16.

Rocha J, Cheng C, Liu W, Kishi S, Das S, Cook E . Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005; 105(12):4752-8. PMC: 1895006. DOI: 10.1182/blood-2004-11-4544. View

17.

French D, Hamilton L, Mattano Jr L, Sather H, Devidas M, Nachman J . A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008; 111(9):4496-9. PMC: 2343589. DOI: 10.1182/blood-2007-11-123885. View

18.

Lopez-Lopez E, Ballesteros J, Pinan M, Sanchez de Toledo J, Garcia de Andoin N, Garcia-Miguel P . Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics. 2012; 23(2):53-61. DOI: 10.1097/FPC.0b013e32835c3b24. View

19.

Cario G, Izraeli S, Teichert A, Rhein P, Skokowa J, Moricke A . High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. J Clin Oncol. 2007; 25(30):4813-20. DOI: 10.1200/JCO.2007.11.8166. View

20.

Peregud-Pogorzelski J, Tetera-Rudnicka E, Kurzawski M, Brodkiewicz A, Adrianowska N, Mlynarski W . Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis. Pediatr Blood Cancer. 2011; 57(4):578-82. DOI: 10.1002/pbc.23013. View